Bhubaneswar: In what could be a positive sign in the fight against COVID-19, leading multinational pharmaceutical company Cipla will soon come up with Favipiravir, an off-patent anti-viral drug, developed by Council of Scientific and Industrial Research (CSIR).
The COVID-19 drug, originally discovered by Japan’s Fuji Pharma, has shown promise in clinical trials for treatment of COVID-19 patients, especially in mild and moderate cases, said an official statement.
CSIR-Indian Institute of Chemical Technology (IICT) developed a cost effective process using locally available chemicals to synthesise this Active Pharmaceutical Ingredient (API) and transferred the technology to Cipla.